Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q1 FY23 results · Apr–Jun 2022
Suven Life Sciences reported revenue from operations of ₹3.54 crore (up 76.4% from Q1 FY22) and net loss of ₹16.33 crore for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3.54 | 2.01 | +76.4% | 4.22 | −16.2% |
| Other income | 0.44 | 4.56 | −90.4% | 0.12 | +268.7% |
| Total income | 3.98 | 6.56 | −39.4% | 4.34 | −8.4% |
| Profit before tax | (16.33) | (39.21) | Loss narrowed | (20.80) | Loss narrowed |
| Net profit for the period | (16.33) | (39.21) | Loss narrowed | (20.80) | Loss narrowed |
| EPS, basic (₹) | (1.12) | (3.08) | not comparable | (1.63) | Loss narrowed |
| Net margin (%) | -461.3 | -1954.5 | -492.7 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3.54 | 2.01 | +76.4% | 4.22 | −16.2% |
| Other income | 0.44 | 4.56 | −90.4% | 0.12 | +269.0% |
| Total income | 3.98 | 6.56 | −39.4% | 4.34 | −8.4% |
| Profit before tax | (2.31) | (8.49) | Loss narrowed | (8.55) | Loss narrowed |
| Net profit for the period | (2.31) | (8.49) | Loss narrowed | (8.55) | Loss narrowed |
| EPS, basic (₹) | (0.16) | (0.67) | not comparable | (0.67) | Loss narrowed |
| Net margin (%) | -65.3 | -423.4 | -202.6 |
Consolidated
- Filed with BSE
- 28 Jul 2022, 14:20 IST
- Board meeting
- 26 Jul 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Jul 2022, 14:20 IST
- Board meeting
- 26 Jul 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE